UnknownPhase 2

Ivermectin Nasal Drops in Post COVID-19 Parosmia

Egypt60 participantsStarted 2022-07

Plain-language summary

The current study will be a pilot study for a randomized controlled trial conducted on patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine To evaluate the effect of ivermectin nasal drops in the treatment of post COVID 19 parosmia

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients should be more than 18 years old, * Patients having a history of COVID 19 infection more than three months ago as confirmed by PCR test, * Patients having a post COVID parosmia, * Patients having no history of systemic steroid administration over the last one month. Exclusion Criteria: * History of previous nasal surgery, * Underlying systemic diseases (like diabetes mellitus, hypertension, or autoimmune diseases), * Hypersensitivity to Ivermectin.

What they're measuring

Comparison between the pre and post treatment values

Timeframe: After one month of treatment

Comparison between case and control groups regarding the post treatment results

Timeframe: After one month of treatment

Trial details

NCT IDNCT05269030

SponsorMenoufia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03

Contact for this trial

Ahmad Hamdan, MD

00201008993175 Ahmed.Hamdan@med.menofia.edu.eg

View on ClinicalTrials.gov More Parosmia trials